NCT06880393View on ClinicalTrials.gov

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

anti-BCMA-CAR-T

Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06880393 - BCMA CAR-T for Dynamic High-risk Multiple Myeloma | Biotech Hunter | Biotech Hunter